Intraductal carcinoma in situ of right breast
ICD-10 D05.11 is a billable code used to indicate a diagnosis of intraductal carcinoma in situ of right breast.
Intraductal carcinoma in situ (DCIS) of the right breast is a non-invasive form of breast cancer characterized by the proliferation of malignant cells within the ducts of the breast tissue without invasion into the surrounding stroma. This condition is often detected through mammography, where microcalcifications may be noted. Patients may be asymptomatic, and the diagnosis is typically confirmed via biopsy. DCIS is classified as stage 0 breast cancer and is considered a precursor to invasive breast cancer. The risk of progression to invasive disease varies, with estimates suggesting that approximately 30-50% of untreated DCIS cases may progress to invasive breast cancer over a 10-year period. Treatment options often include surgical excision, radiation therapy, and hormonal therapy, depending on the tumor characteristics and patient preferences. Regular surveillance and follow-up are crucial for monitoring potential progression and managing treatment outcomes.
Detailed pathology reports, treatment plans, and follow-up notes.
Diagnosis confirmation through biopsy, treatment planning, and monitoring for recurrence.
Ensure clarity in treatment intent (curative vs. palliative) and document any multidisciplinary discussions.
Clear imaging reports indicating findings suggestive of DCIS, including descriptions of calcifications.
Mammography findings leading to biopsy recommendations.
Accurate reporting of imaging findings is crucial for appropriate coding.
Used when a patient with D05.11 undergoes a lumpectomy.
Operative report detailing the procedure and findings.
Oncology specialists should ensure comprehensive documentation of tumor characteristics.
Coding D05.11 accurately reflects the diagnosis of intraductal carcinoma in situ, which is crucial for treatment planning, surveillance, and research purposes. It helps in tracking the incidence and outcomes of non-invasive breast cancer.
